Winrevair (sotatercept), a treatment for pulmonary arterial hypertension (PAH), has emerged as a promising candidate with the potential to reshape the PAH treatment landscape. Analysts are eagerly ...

Recent developments in Merck's pipeline have drawn considerable attention from investors and analysts. Winrevair (sotatercept), a treatment for pulmonary arterial hypertension (PAH), has emerged as a ...

Credit: Getty Images The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Nikola (NASDAQ:NKLA) was down 29% in afternoon trading on Thursday and swapped hands as low as $0.76 amid bankruptcy speculation. Electrek's Fred Lambert wrote on social media site X that a source ...

With that acquisition, they got this drug called Winrevair. It is approved by the FDA, just this last year for an almost always fatal disease called pulmonary arterial hypertension.” Cramer ...